Interview | Beyond the Contract: What Makes a Pharma-CDMO Partnership Truly Strategic?

A contract can define the terms of a relationship, but it cannot create trust, alignment, or shared accountability.

In this exclusive speaker interview, Ulrich Rümenapp, Senior Biotech Program Lead at Bayer AG, explores what it takes to build pharma–CDMO partnerships that deliver value beyond a single project.

Drawing on his experience, Ulrich examines how pharma companies and CDMOs can strengthen collaboration, balance price, quality, and speed, manage risk and prepare for increasingly complex therapeutic modalities.

Download the interview to learn more about:

• What separates a strategic partnership from a relationship that simply meets contractual obligations
• How pharma and CDMOs can better balance price, quality, and speed
• Why open communication, trust, and clear accountability are critical to performance

Download and read the full interview to explore how stronger partnerships can help pharma companies and CDMOs navigate the increasing complexity of pharmaceutical manufacturing.